<DOC>
	<DOCNO>NCT02029638</DOCNO>
	<brief_summary>The purpose study find study treatment allow people accept new kidney able stop take anti-rejection medication .</brief_summary>
	<brief_title>Bone Marrow Transplantation ( BMT ) High Dose Post-Transplant Cyclophosphamide Chimerism Induction Renal Allograft Tolerance</brief_title>
	<detailed_description>Transplantation good treatment people end-stage kidney disease . However , still much learn best care transplant kidney keep work long time . Unless person receive kidney someone else take drug reduce immune function , kidney reject . Those drug must continue life-long cause many issue . Therefore , tolerance transplant kidney , without chronic rejection without need permanent immunosuppressive drug treatment , highly desirable goal . If achieve , would make `` one kidney life '' possible . The study treatment include several day study medication follow kidney bone marrow transplant . After transplant , study treatment continue dos study medication anti-rejection medication start . After , anti-rejection medication slowly stop . Researchers examine blood tissue sample try identify genetic marker certain condition like chimerism , response therapy , tolerance .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Recipient participant must meet follow criterion eligible study : Recipient first renal allograft Human Leukocyte Antigen ( HLA ) haploidentical , live relate donor . The donor recipient must HLA identical least one allele ( use high resolution DNA base type ) follow genetic locus : HLAA , HLAB , HLAC HLADRB1 . Fulfillment criterion shall consider sufficient evidence donor recipient share one HLA haplotype . Age 18 65 year . Single solid organ recipient ( kidney ) . Blood Group System ( ABO ) compatibility donor . DonorSpecific Antibody ( DSA ) assess local laboratory 30 day less prior transplant use solid phase micro particle technology ( Luminex® phenotype panel Luminex single antigen bead test . ) The follow criterion apply : Participants without detectable DSA deem eligible meet entry criterion . Participants detectable DSA positive flow cytometric crossmatch may undergo desensitization per standard care cytotoxic crossmatch negative . Such participant must demonstrate negative flow cytometric crossmatch day 9 order receive first dose study therapy ( ATG ) . Participants demonstrate acceptable response desensitization day 9 consider screen failure terminate study . Participants positive cytotoxicity crossmatch exclude . No known history antiHLA antibody . Recipients low level antiHLA antibody consider clinically significant may eligible , follow consultation Protocol Chairs , local HLA Laboratory Director , NIAID Medical Monitor ITN Clinical Trial Physician . Negative T B cell flow crossmatches designate donor ; assess local laboratory . If one crossmatches positive , participant consider screen failure unless combine result antibody cross match test implicate nonHLA antibody cause positive flow crossmatch . In case , Protocol Chair must approve participant screen success consultation local HLA Laboratory Director . Normal estimate leave ventricular ejection fraction history ischemic heart disease require revascularization , unless clear cardiologist . Forced expiratory volume ( FEV1 ) force vital capacity ( FVC ) &gt; 40 % predict screening visit . Serological evidence prior EpsteinBarr virus ( EBV ) infection document positive IgG negative IgM antibody EBV . For woman childbearing potential , negative serum urine pregnancy test sensitivity le 50 MilliInternational unit ( mIU ) /m within 72 hour start study medication . Use two form contraception le 5 % failure rate abstinence transplant participant 18 month first dose study therapy . For first 60 day posttransplant , recipient encourage use nonhormonal contraceptive due potential adverse effect hormone bone marrow engraftment . Ability receive oral medication . Ability understand provide inform consent . All participant must demonstrate negative QuantiFERON® ( QFT ) assay result within 52 week transplant regardless Purified Protein Derivative ( PPD ) status . Participants positive QFT assay eligible study unless complete treatment latent TB negative chest xray . QFT test do within 52 week transplant acceptable long documentation result . Prior recipient Bacillus CalmetteGuérin ( BCG ) vaccination exempt . Donor participant must meet follow criterion eligible study : HLAhaploidentical , firstdegree relative halfsiblings recipient participant allele allele group . The donor recipient must HLA identical least one allele ( use high resolution DNA base type ) follow genetic locus : HLAA , HLAB , HLAC , HLADRB1 . Fulfillment criterion shall consider sufficient evidence donor recipient share one HLA haplotype . Age 18 65 year . Creatinine clearance &gt; 80 ml/minute measure 24 hour urine collection within 26 week screen visit . If serum creatinine draw screen visit &gt; 20 % high serum creatinine draw time 24 urine collection , creatinine clearance must reevaluate repeat 24 hour urine test . If new value ≤80mg/dL donor exclude . Meets institutional selection criterion organ bone marrow donation . Ability understand provide inform consent study procedure include kidney transplant bone marrow harvest . Serologic evidence prior EBV infection document positive Immunoglobulin G ( IgG ) negative Immunoglobulin M ( IgM ) antibodies EBV . Recipient subject meet follow criterion eligible study : Underlying renal disease high risk disease recurrence transplant kidney , include : 1 . Focal segmental glomerulosclerosis ( FSGS ) . 2 . Type I II membranoproliferative glomerulonephritis . 3 . Hemolyticuremic syndrome/thrombotic thrombocytopenic purpura . Clinically important genital/urinary tract dysfunction . Body mass index ( BMI ) &gt; 40 . Women breastfeed . History cancer within last 5 year , except nonmelanoma skin cancer , stage 1 renal cell carcinoma , stage 1 prostate cancer cure local resection curatively treat carcinomas situ . History positive HIV1 HIV2 serology nucleic acid test . Evidence prior hepatitis B infection evaluate hepatitis B surface antigen ( HBsAg ) , total hepatitis B core antibody ( antiHBc IgM IgG ) Hepatitis B surface antibody ( antiHBsAb ) . Subjects demonstrate one follow exclude : Positive hepatitis B surface antigen ( HBsAg ) Positive antiHBc IgM . Positive antiHBc IgG . Positive Hepatitis B virus ( HBV ) Polymerase chain reaction ( PCR ) . Positive antihepatitis C ( HCV ) antibodies positive serum HCV RNA PCR . All positive HCV antibody result must assess Electroimmunoassay ( EIA ) assay confirm quantitative serum HCV RNA assay . Participants positive HCV antibody undetectable serum HCV RNA may consider eligibility . Participants negative antiHCV antibody unexplained liver enzyme abnormality must undergo quantitative serum RNA assay rule false negative HCV serology . History active Tuberculosis ( TB ) . Any active , severe local systemic infection screen visit . Autoimmune disease require immunosuppressive drug maintenance . Use investigational drug , study medication specify protocol , within 30 day transplantation . Receipt live vaccine within 30 day receipt study therapy . The presence medical condition Investigator deem incompatible participation trial . Donor subject meet follow criterion eligible study : History type I type II diabetes mellitus . History severe cardiovascular disease , define New York Heart Association Class III IV2 . History blood product donation recipient . History positive HIV1 HIV2 serology nucleic acid test . Evidence prior hepatitis B infection . Subjects demonstrate one follow exclude : Positive hepatitis B surface antigen ( HBsAg ) Positive anti hepatitis B core antigen ( HBc ) IgM . Positive antiHBc IgG . Positive HBV PCR Positive antihepatitis C ( HCV ) antibodies positive serum HCV RNA PCR . All positive HCV antibody result must assess EIA assay confirm quantitative serum HCV RNA assay . Participants positive HCV antibody undetectable serum HCV RNA may consider eligibility . Participants negative antiHCV antibody unexplained liver enzyme abnormality must undergo quantitative serum RNA assay rule false negative HCV serology . Autoimmune disease require immunosuppressive drug maintenance . The presence medical condition Investigator deem incompatible participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Renal Transplantation</keyword>
</DOC>